A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve

Cancer Chemotherapy and Pharmacology
S Ghazal-AswadD R Newell

Abstract

The aim of this study was to develop and validate a simple and rapid method for the estimation of the area under the free carboplatin plasma concentration versus time curve (AUC). The relationship between the carboplatin AUC and the total plasma platinum (Pt) concentration 24 h after treatment was studied using data from 49 patients treated with 20-1600 mg/m2 carboplatin as a 60-100 min infusion (median 60 min). The relationship was confirmed by the in vitro incubation of carboplatin in human plasma and prospectively validated in 13 ovarian cancer patients. Free carboplatin was separated by ultrafiltration (MW cut off 30,000), and free and total Pt measured by atomic absorption spectrophotometry. There was a linear relationship in vivo between the 24 h (median 24.4; range 16.3-27.3 h) total plasma Pt concentration (microM) and free carboplatin AUC (mg/ml.min): AUC=(24 h Pt+0.3)/0.82 (r2=0.93, AUC median 5.8 (0.13-28)mg/ml.min, 24h Pt median 4.4 (0.1-23) microM). A similar relationship was observed in vitro [AUC =(24h Pt +0.1)/0.93 (r2=0.98, AUC median 7.9 (2.0-17) mg/ml.min, 24 h Pt median 7.1 (1.8-15) microM)]. The relationship derived from the in vivo data gave an unbiased and reasonably accurate estimate of the measured carb...Continue Reading

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D I JodrellE Wiltshaw
Jan 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A HorwichW F Hendry
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S J HarlandA Horwich
Oct 1, 1991·Clinical Pharmacokinetics·W J van der Vijgh
Jan 1, 1991·Cancer Chemotherapy and Pharmacology·B T SørensenA Jakobsen
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·D R NewellA H Calvert
Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A H CalvertE Wiltshaw
Sep 1, 1987·European Journal of Cancer & Clinical Oncology·D R NewellA H Calvert
Aug 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·L B Sheiner, S L Beal
Jan 1, 1994·Cancer Chemotherapy and Pharmacology·L J van WarmerdamJ H Beijnen
Jan 1, 1993·Cancer Chemotherapy and Pharmacology·B T SørensenA Jakobsen

❮ Previous
Next ❯

Citations

Sep 28, 1998·Cancer Chemotherapy and Pharmacology·M J Egorin
Apr 29, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·X PivotG Milano
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B PengD R Newell
Feb 5, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J P SculierJ Klastersky
Mar 31, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E ChatelutP Canal
Oct 19, 2000·Anti-cancer Drugs·A D HuitemaJ H Beijnen
Oct 14, 2011·BMC Cancer·Rita OtvösLaszlo Szekely
Dec 7, 2000·Clinical Pharmacokinetics·H J van den BongardJ H Schellens
Mar 2, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T R CresseyD R Newell
Sep 6, 2007·Leukemia & Lymphoma·Laszlo MarkaszLaszlo Szekely
Aug 26, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Panos FidiasJeffrey G Supko
Aug 5, 2003·British Journal of Clinical Pharmacology·Toru IshibashiTakayoshi Oguma
Dec 2, 2011·British Journal of Clinical Pharmacology·Jennifer H MartinDavid Looke
Mar 16, 2007·Clinical Oncology : a Journal of the Royal College of Radiologists·S A Kaestner, G J Sewell
Nov 2, 2005·Biochemical Pharmacology·Emma L MeczesMichael J Tilby
Aug 7, 2004·The Veterinary Clinics of North America. Exotic Animal Practice·Lucio J Filippich, Bruce G Charles
Sep 18, 2007·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Sabine Kaestner, Graham Sewell
Aug 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andy HughesHilary Calvert
May 1, 1997·Cancer Treatment Reviews·G FreyerV Trillet-Lenoir
May 16, 2012·Therapeutic Drug Monitoring·Mohamed SaleemJennifer H Martin
Nov 2, 2019·Investigational New Drugs·Ruud van der NollJan H M Schellens
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A PatnaikA M Oza
Feb 20, 2007·Molecular Cancer Therapeutics·Laszlo MarkaszLaszlo Szekely

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.